AI Stock Analysis - Amgen (AMGN)
Analysis generated November 10, 2025.
Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company that develops, manufactures, and delivers innovative human therapeutics. Established in 1980, Amgen has a strong reputation for its work in areas like oncology, nephrology, and inflammation, with a portfolio that includes highly successful products such as Neulasta, Enbrel, and Prolia. The company's extensive pipeline of investigational drugs promises continued growth and innovation in the biotech field.
Stock Alerts - Amgen (AMGN)
 |
Amgen | January 14 Julia Letlow (member of U.S. congress) is selling shares |
|
Amgen | January 6 AI Score is down by -20.5% in the last couple of days. |
|
Amgen | January 6 News Alert: Amgen acquires Dark Blue Therapeutics in deal valued at up to $840M |
|
Amgen | December 12 News Alert: FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease |
Download our app to get future alerts delivered in real-time.
Alternative Data for Amgen
About Amgen
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
| Price | $330.41 |
| Target Price | Sign up |
| Volume | 3,980,000 |
| Market Cap | $178B |
| Year Range | $256.11 - $345.46 |
| Dividend Yield | 2.85% |
| PE Ratio | 25.57 |
| Analyst Rating | 53% buy |
| Earnings Date | February 3 '26 |
| Industry | Biotechnology |
In the news
 |
Amgen’s Weight-Loss Drug Shows Promise With Less Frequent DosingJanuary 15 - Yahoo |
|
Amgen Inc. (AMGN): A Bull Case TheoryJanuary 15 - Yahoo |
|
Amgen (AMGN) Advances While Market Declines: Some Information for InvestorsJanuary 14 - Yahoo |
Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJanuary 14 - MarketWatch |
|
|
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value EstimateJanuary 13 - Yahoo |
 |
Amgen CEO says weight loss drug can address 'patient persistence issue'January 13 - CNBC |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 9.56B | 3.08B | 6.48B | 3.22B | 5.91B | 5.640 |
| Q2 '25 | 9.17B | 3.01B | 6.16B | 1.43B | 3.62B | 6.020 |
| Q1 '25 | 8.15B | 2.97B | 5.18B | 1.73B | 4.08B | 4.900 |
| Q4 '24 | 9.09B | 3.11B | 5.97B | 627M | 2.93B | 5.310 |
| Q3 '24 | 8.5B | 3.31B | 5.19B | 2.83B | 5.27B | 5.580 |
Insider Transactions View All
| Grygiel Nancy A. filed to sell 7,225 shares at $337.3. November 21 '25 |
| Grygiel Nancy A. filed to sell 7,225 shares at $337.3. November 21 '25 |
| Khosla Rachna filed to sell 7,082 shares at $336.2. November 13 '25 |
| Gordon Murdo filed to sell 41,923 shares at $336.8. November 13 '25 |
| Grygiel Nancy A. filed to sell 7,209 shares at $297. August 22 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julia Letlow |
Jan 14, 26 | Sell | $1K - $15K |
| Julia Letlow |
Jan 14, 26 | Buy | $1K - $15K |
| David Taylor |
Dec 8, 25 | Sell | $1K - $15K |
Read more about Amgen (AMGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Amgen
The Market Cap of Amgen is $178B.
As of today, Amgen's PE (Price to Earnings) ratio is 25.57.
Amgen will report its next earnings on February 3 '26.
Currently, the price of one share of Amgen stock is $330.41.
The AMGN stock price chart above provides a comprehensive visual representation of Amgen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amgen shares. Our platform offers an up-to-date AMGN stock price chart, along with technical data analysis and alternative data insights.
Yes, Amgen (AMGN) offers dividends to its shareholders, with a dividend yield of 2.85%. This dividend yield represents Amgen's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Amgen in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Amgen are Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
